What is HC Wainwright’s Forecast for BTAI Q1 Earnings?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of BioXcel Therapeutics in a research report issued on Thursday, April 2nd. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.48) for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($24.39) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.52) EPS and FY2027 earnings at ($1.12) EPS.

Several other research firms have also recently commented on BTAI. Wall Street Zen cut BioXcel Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. Zacks Research upgraded BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, March 9th. Rodman & Renshaw began coverage on BioXcel Therapeutics in a research note on Tuesday, March 17th. They set a “buy” rating and a $17.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $11.00.

BioXcel Therapeutics Price Performance

BTAI opened at $1.09 on Tuesday. BioXcel Therapeutics has a 12 month low of $1.06 and a 12 month high of $8.08. The stock has a market cap of $29.52 million, a P/E ratio of -0.16 and a beta of 0.30. The stock’s 50 day moving average price is $1.52 and its 200 day moving average price is $1.87.

BioXcel Therapeutics (NASDAQ:BTAI) last posted its earnings results on Friday, March 27th. The company reported ($0.58) EPS for the quarter, meeting the consensus estimate of ($0.58). The business had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.15 million.

Hedge Funds Weigh In On BioXcel Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Diversify Wealth Management LLC bought a new position in BioXcel Therapeutics during the 2nd quarter valued at $27,000. HRT Financial LP bought a new position in BioXcel Therapeutics during the 4th quarter valued at $28,000. XTX Topco Ltd bought a new position in BioXcel Therapeutics during the 2nd quarter valued at $42,000. Goldman Sachs Group Inc. bought a new position in BioXcel Therapeutics during the 1st quarter valued at $50,000. Finally, Geode Capital Management LLC boosted its stake in BioXcel Therapeutics by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock valued at $51,000 after purchasing an additional 6,120 shares in the last quarter. 30.68% of the stock is owned by institutional investors.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.